Short CV:

After completing a PhD in the UK at the University of Liverpool, Catherine moved to Sweden and joined Magnus Ingelman-Sundberg’s group at Karolinska Institute where she contributed to the development and characterization of a 3D hepatic spheroid model for predicting drug toxicity. During this project, Catherine was also involved in a consortium between academic and industry partners (MIP-DILI), where she led a ring trial to determine the reproducibility of the spheroid model across multiple labs. This led her to consider continuing a career in industry, and she decided to start a second postdoc at AstraZeneca, where she has been for the last six years. Catherine is currently an Associate Director, supporting the pre-clinical safety of projects aiming to treat cardiovascular, renal and metabolic diseases.